Epigenetics Market to Observe Strong Development by 2022
The
global epigenetics market is expected to reach USD 16.31
billion by 2022, according to a new report by Grand View Research, Inc. Growing
worldwide prevalence of cancer and other diseases with epigenetic modification
base is expected to drive market growth during the forecast period.
Diagnostic
companies are coming up with new products such as antibodies specific for the
detection of modifications and new upgraded kits for easy and efficient
detection of biomarkers. This is expected to attract pharmaceutical companies
to collaborate for the development of therapeutic drugs.
Presence
of pipeline drugs and their expected commercialization is anticipated to boost
penetration rates over the forecast period. For instance, Ramucirumab (Cyramza)
by Eli Lilly and Company was approved by the FDA for use in combination with
Folfiri for the treatment of patients with metastatic colorectal cancer.
Technology
advancements in the field of epigenetics especially pertaining to the detection
of methylation markers related to cancer development is expected to improve
usage rates during the forecast period. For instance, Epi proLung BL Reflex
Assay by Epigenomics helps in the diagnosis of lung cancer by determining
methylation of SHOX2 biomarker gene.
Browse full
research report on Epigenetics Market:
www.grandviewresearch.com/industry-analysis/epigenetics-market
Further key
findings from the study suggest:
- Epigenetic reagents was the largest market
valued at over USD 1.2 billion in 2014 owing to the increasing amount of
R&D investments and high consumption rates. Kits are expected to gain
rapid growth in demand due to the increasing need of rapid and accurate
detection techniques.
- DNA methylation was the largest technology segment
accounting for over 47.0% revenue in 2014. The introduction of
technological advancement such as Methylation Sensitive PCR (MSP) and
rapid adoption of these products to improve diagnostics efficiency are
some factors attributing for its largest share.
- Oncology was the largest application market,
with revenue valued at over USD 2.75 billion. Growing prevalence of cancer
with epigenetic modification base and strong product pipeline are some
factors attributing to its market position.
- Non oncology segment is anticipated to register
the fastest growth of over 20.0% during the forecast period. The segment
is dominated by metabolic diseases owing to, the growing base of
population suffering from diabetes and organ failure and increasing
prevalence of sedentary lifestyle.
- North America was observed to be the largest
regional epigenetics market accounting for over 38.0% of the overall
revenue, due to factors such as the increasing cancer prevalence,
increasing amount of funding for R&D, growing collaborations between
large pharmaceutical firms for development of improved therapeutics, high
patient awareness levels.
- The Asia Pacific market is estimated to witness
lucrative growth over the forecast period owing to, the presence of large
prevalence of target diseases and high unmet medical needs
- Some key players of the epigenetics market
include Illumina, Abcam, Diagenode, Thermo Fisher Scientific, Merck, Zymo
research, Qiagen, CellCentric Ltd, Chroma Therapeutics Ltd, Eisai Co. Ltd,
Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals,
Inc., Valirx Plc and Sigma-Aldrich Corporation.
- Extensive R&D initiatives aimed at the
development of novel drugs and the presence of strong product pipeline is
expected to further boost market growth over the forecast period.
Browse more
reports of this category by Grand View Research: www.grandviewresearch.com/industry/medical-devices
Grand View Research has segmented the global epigenetics market on the
basis of product, technology, application and region:
Epigenetics
Product Outlook (Revenue, USD Million, 2015 - 2022)
- Reagents
- Kits
- Instruments
- Enzymes
- Services
Epigenetics
Technology Outlook (Revenue, USD Million, 2015 - 2022)
- DNA
Methylation
- Histone
Methylation
- Histone
Acetylation
- Large
noncoding RNA
- MicroRNA
Modification
- Chromatin
structures
Epigenetics
Application Outlook (Revenue, USD Million, 2015 - 2022)
- Oncology
- Solid
Tumors
- Liquid
Tumors
- Non
Oncology
- Inflammatory
Diseases
- Metabolic
Diseases
- Infectious
Diseases
- Cardiovascular
Diseases
Epigenetics
Market Regional Outlook(Revenue, USD Million, 2015 - 2022)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia
Pacific
- Japan
- China
- India
- Latin
America
- Brazil
- Mexico
- Middle
East and Africa (MEA)
- South
Africa
Access
Press Release By Grand View Research: www.grandviewresearch.com/press-release/global-epigenetics-market
About Grand
View Research:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Comments
Post a Comment